Biosensors and Nanotheranostics

1. Introduction

Cancer immunotherapy has reset the terms of modern oncology by recruiting the host immune system to recognize and eliminate malignant cells. Within this landscape, cancer nanovaccines have emerged as a particularly attractive platform for inducing durable, tumor-specific responses (Guo et al., 2024; Li et al., 2025). The appeal is easy to state and hard to deliver on. Conventional vaccines built from soluble tumor-associated antigens (TAAs) or peptide fragments, formulated with classical adjuvants, are undermined by rapid enzymatic degradation, poor systemic stability, weak accumulation in secondary lymphoid organs, and inefficient capture by professional antigen-presenting cells (APCs) (Farooq et al., 2025; Guo et al., 2024). Nanovaccines were conceived precisely to close those gaps, using engineered carriers, polymeric and lipid nanoparticles, inorganic nanostructures, and biomimetic cell-membrane vesicles, to co-deliver antigens together with potent immunomodulatory adjuvants such as Toll-like receptor (TLR) agonists or stimulator of interferon genes (STING) activators (Huang et al., 2026; Li et al., 2025).

The decisive events of antitumor priming do not occur at the injection site; they occur in the secondary lymphoid tissue, and specifically in the tumor-draining lymph nodes (LNs) (Zhu et al., 2017). LNs concentrate naive T and B lymphocytes alongside organized networks of dendritic cells (DCs) and resident macrophages (Jewell et al., 2011). Delivering antigen and adjuvant efficiently to these nodes is therefore not a convenience but a prerequisite: it is what triggers DC maturation, enables major histocompatibility complex (MHC) class I and II antigen cross-presentation, and primes the antigen-specific cytotoxic T lymphocytes (CTLs) capable of infiltrating distant primary and metastatic lesions (Bao et al., 2026; Jin et al., 2024). Directing nanovaccines to draining LNs has thus become a central design objective (Guo et al., 2024).

Lymphatic uptake and intranodal accumulation of subcutaneously or intradermally administered nanovaccines are governed, quite strictly, by physical and chemical properties, particle size, surface charge, morphology, and surface functionalization (Farooq et al., 2025). Initial lymphatic capillaries present loose endothelial junctions that admit nano-sized constructs by convection (Golshan et al., 2017). Particles in the 10–100 nm window, and especially 20–50 nm, drain efficiently into afferent lymphatics and accumulate in draining LNs, whereas ultra-small species (<6–10 nm) escape into blood capillaries and are cleared renally, and larger particles (>100–200 nm) remain depot-trapped or depend on cell-mediated transport by tissue-resident DCs (Farooq et al., 2025; Guo et al., 2024). Surface charge and active targeting then dictate which cells internalize the cargo: near-neutral or anionic surfaces favor interstitial transit, while ligands such as mannose, membrane coatings, or antibody fragments drive receptor-mediated uptake and endosomal escape (Jin et al., 2024; Li et al., 2025).

Despite this sophistication in design, evaluation has lagged. Preclinical assessment has leaned on invasive end-point organ harvests and semiquantitative assays, leaving a real “delivery gap” around the spatial and temporal kinetics of where a nanovaccine actually goes (Uti et al., 2026; Zhu et al., 2017). Because lymphatic drainage varies between individuals, uniform distribution models are unreliable, which is the argument for “see-and-correct” theranostic frameworks (Uti et al., 2026). Embedding imaging tags directly into the nanovaccine architecture unifies therapeutic activation with real-time tracking in vivo, drawing on optical and near-infrared fluorophores, nuclear radiotracers, magnetic contrast agents, and genetic reporters (Kemp & Kwon, 2021; Wang et al., 2026; Xiang et al., 2015; Zhu et al., 2017). These capabilities convert a blind injection into a measurable, digitally traceable process that can be correlated with immunotherapeutic efficacy (Uti et al., 2026).

Several obstacles still separate theranostic nanovaccines from the clinic. Tracer dissociation or fluorophore leaching can generate false-positive signals that misrepresent intact-particle movement (Farooq et al., 2025). Non-specific sequestration by the reticuloendothelial system, chiefly liver and spleen, reduces net nodal delivery and raises off-target toxicity concerns (Bao et al., 2026). Batch-to-batch reproducibility, multicomponent complexity, Good Manufacturing Practice (GMP) compliance, and standardized immunotoxicology remain genuine barriers (Uti et al., 2026; Zhu et al., 2017). Against that backdrop, this review pursues four objectives: to codify the physicochemical design rules for lymphatic delivery; to compare built-in imaging modalities by sensitivity, depth, resolution, and quantitative accuracy; to correlate in vivo kinetics with immunological outcomes including DC maturation, CTL priming, tertiary lymphoid structure (TLS) formation, and memory; and to identify the translational bottlenecks that will decide clinical adoption (Farooq et al., 2025; Uti et al., 2026; Ye et al., 2026).

2. Methods

2.1. Study design and reporting framework

This work was conducted as a structured narrative review of the preclinical literature on immunomodulatory nanovaccines carrying built-in imaging tags for in vivo lymph-node tracking. Because the aim was mechanistic synthesis rather than pooled effect estimation, we did not perform a quantitative meta-analysis; instead, the review follows the narrative-synthesis principles consistent with PRISMA-style reporting for identification, screening, eligibility, and inclusion, so that the selection pathway is transparent and, in principle, reproducible by an independent reader.

2.2. Information sources and search strategy

Peer-reviewed sources were identified through PubMed/MEDLINE, Scopus, and Web of Science, supplemented by forward and backward citation chasing of key articles. Searches combined controlled vocabulary and free-text terms across three concept blocks joined with the Boolean operator AND, with synonyms within each block joined by OR. Block 1 (delivery system): “nanovaccine” OR “cancer vaccine” OR “lipid nanoparticle” OR “PLGA” OR “biomimetic nanoparticle.” Block 2 (target process): “lymph node” OR “lymphatic drainage” OR “dendritic cell” OR “antigen-presenting cell” OR “cross-presentation.” Block 3 (tracking): “in vivo imaging” OR “near-infrared” OR “PET” OR “SPECT” OR “MRI” OR “magnetic particle imaging” OR “bioluminescence” OR “theranostic.” No proprietary filters were applied beyond language and document type.

2.3. Eligibility criteria

Studies were eligible if they (i) described an engineered nanoscale vaccine or antigen–adjuvant delivery system, (ii) reported lymph-node trafficking, APC engagement, or an immunological outcome, and (iii) incorporated or directly characterized an imaging/tracking readout or the physicochemical determinants of nodal delivery. Peer-reviewed original research and authoritative reviews published in English were included. Conference abstracts without primary data, non-English reports, and records lacking either a delivery or a tracking component were excluded. Where several reports described the same platform, the most complete primary source was retained.

2.4. Study selection and data extraction

Records were screened first by title and abstract and then by full text against the criteria above. From each included study we extracted, into a standardized matrix, the nanocarrier composition, hydrodynamic size and morphology, surface charge and surface modifications, administration route and target cell population, the antigen and adjuvant payload, the imaging modality and contrast agent, the quantitative tracking metric (for example, percentage injected dose per gram, %ID/g), and the downstream immunological and antitumor outcomes. These extracted variables map directly onto the four synthesis tables reported here (Table 1; Table 2; Table 3; Table 4).

2.5. Synthesis and figure construction

Extracted evidence was synthesized thematically along four axes, physicochemical trafficking rules, antigen–adjuvant architecture, imaging modality performance, and immunological outcome, which also organize the Literature Review. The four schematic figures (Figure 1; Figure 2; Figure 3; Figure 4) were constructed by the authors as graphical summaries of these synthesized relationships; they depict consensus parameter ranges and mechanistic sequences rather than data from any single study, and each cites the sources on which it draws. Numerical ranges quoted in the text (size windows, zeta-potential bands, %ID/g values, fold-changes) are reproduced as reported in the primary sources and were not recalculated (Farooq et al., 2025; Rachamala et al., 2026; Zhu et al., 2017).

3. Advanced Immunomodulatory Nanovaccines and In Vivo Lymph-Node Tracking Strategies

Cancer immunotherapy depends, in the end, on generating robust and durable tumor-specific adaptive immunity, and the tumor-draining lymph nodes (TDLNs) are where that program is actually written (Guo et al., 2024). Soluble vaccines falter because they are degraded, cleared, and poorly retained in nodes; nanovaccines answer this by packaging TAAs, neoantigens, or whole-tumor-cell lysates with immunostimulatory adjuvants inside nanoscale carriers (Li et al., 2025). The sections below move from the physics of drainage to the immunology of outcome, and the four synthesis tables (Table 1; Table 2; Table 3; Table 4) and four figures (Figure 1; Figure 2; Figure 3; Figure 4) anchor each step.

3.1. Physicochemical rules governing lymphatic drainage and APC internalization

The passage of parenterally injected nanovaccines from the interstitium into afferent lymphatics, and their subsequent retention in draining nodes, is regulated by hydrodynamic diameter, surface charge, shape, elasticity, and targeting ligands, as summarized in Table 1 and Figure 1 (Farooq et al., 2025).

3.1.1. Size-dependent drainage kinetics

Size is the principal gating parameter. Interstitial tissue, a tangle of collagen and anionic hyaluronic acid, presents lymphatic endothelial gaps of roughly 20–100 nm (Farooq et al., 2025; Li et al., 2025). Ultra-small particles (<10 nm) diffuse into blood capillaries and are cleared renally

Table 1. Physicochemical parameters and lymphatic disposition of representative engineered nanovaccines. For each platform the table lists carrier composition, hydrodynamic size and morphology, surface charge and functional modifications, administration route and target cells, and the principal lymph-node drainage and antigen-presenting-cell uptake outcomes reported. The systems span passive size-optimized (OVA-GNPs, SPPA, AlbiVax), charge- and elasticity-tuned (SMONV), and actively targeted (M-LNP, PLGA-aCD40, PLO) designs, illustrating how size, charge, geometry, and ligands jointly govern nodal delivery.

Table 2. Antigen–adjuvant formulation architectures and immunological signaling. The table maps representative nanovaccine platforms to their antigen payload, adjuvant combination and innate signaling pathway, delivery vector or membrane coating, and the resulting antigen-presenting-cell mechanism and cross-presentation route. Platforms range from biomimetic membrane-coated and carrier-free systems to dual TLR/STING and outer-membrane-vesicle designs, showing how payload breadth and adjuvant synergy together shape MHC-I cross-presentation and CD8+ T-cell priming.

(Guo et al., 2024; Huang et al., 2026), whereas constructs in the 10–100 nm window, optimally 20–50 nm, enter initial lymphatics by convection and drain passively into nodes (Farooq et al., 2025; Uti et al., 2026). Ovalbumin-functionalized gold nanoparticles of 22 and 33 nm, for instance, accumulated in popliteal nodes far more than their 10 nm counterparts, which diffused into blood instead (Guo et al., 2024). Above 100–200 nm, passive entry collapses; particles form a depot from which tissue-resident DCs slowly ferry cargo nodeward over days rather than hours (Golshan et al., 2017). Comparative PLGA nanovaccines illustrate the steepness of this threshold: 83 nm formulations drained well, while 103 and 122 nm variants did not (Li et al., 2025) (Table 1).

3.1.2. Surface charge, matrix sequestration, and charge-reversal

Charge sets the balance between mobility and uptake. Near-neutral or anionic surfaces minimize electrostatic binding to the anionic extracellular matrix and transit efficiently, but resist direct endocytosis by APCs (Farooq et al., 2025). Cationic particles bind APC membranes avidly and aid endosomal disruption, yet become entrapped locally and opsonized systemically (Li et al., 2025). Charge-reversal chemistry resolves the conflict: a slightly negative surface during drainage flips to cationic in the acidic subcapsular sinus or endosome, triggering DC internalization on arrival (Li et al., 2025) (Figure 1).

3.1.3. Geometry, elasticity, and active receptor targeting

Shape and deformability tune intranodal fate. Gold nanostars localize to B-cell follicles and favor humoral responses, while nanocages persist in paracortical T-cell zones and amplify cellular immunity (Huang et al., 2026). Soft, elastic mesoporous organosilica nanovaccines deform through endothelial gaps more readily than rigid particles, yielding roughly a 10-fold rise in cross-presentation markers (Li et al., 2025). Layered onto this, ligand decoration adds selectivity: mannose engages C-type lectin receptors on APCs (Jin et al., 2024), and anti-CD40 antibody grafted onto PLGA drives CD80/CD86 upregulation and cross-presentation (Huang et al., 2026) (Table 1).

3.2. Antigenic repertoires and adjuvant co-delivery architecture

Potent CTL responses require antigen and adjuvant to reach the cytosol of node-resident APCs together, a logic captured in Table 2 and Figure 2.

3.2.1. Whole-cell lysates, biomimetic coatings, and carrier-free platforms

Single-peptide vaccines are vulnerable to antigen-loss escape under tumor heterogeneity (Ye et al., 2026). Whole-tumor-cell lysates and cancer-cell membranes supply a broad, patient-specific antigen repertoire, and biomimetic coatings preserve membrane antigens in native conformation while homing receptors aid migration (Guo et al., 2024; Li et al., 2026; Ye et al., 2026). Carrier-free designs go further: complexing fluorinated CpG with tumor peptide reached antigen loading of 83.19 wt%, removing carrier toxicity while boosting uptake (Huang et al., 2026; Li et al., 2025) (Table 2).

3.2.2. Dual-adjuvant synergies and plant-derived adjuvants

Pairing adjuvants within one carrier engages complementary innate pathways. Combining TLR7/8 or TLR4 agonists with cGAS-STING activators drives type I interferon and proinflammatory cytokine output (Huang et al., 2026; Rachamala et al., 2026). The SPPA platform co-delivers lipid-conjugated neoantigen peptides with 3M-052 (TLR7/8) and 2'3'-cGAMP (STING), upregulating MHC-I/II and costimulatory molecules (Rachamala et al., 2026). Naturally derived polysaccharides also serve: the Lycium barbarum fraction NLBPE1 in PLGA (the PLO nanovaccine) promoted DC maturation and tripled nodal antigen retention relative to free peptide (Bao et al., 2026) (Table 2).

3.3. Theranostic modalities for in vivo spatiotemporal tracking

Replacing post-mortem harvests with non-invasive readouts is what makes delivery a controllable variable; the modalities and their trade-offs are compared in Table 3 and positioned in Figure 3 (Uti et al., 2026).

3.3.1. Optical and near-infrared (NIR-I/NIR-II) fluorescence

NIR fluorophores (DiD, Rhodamine-PE, Cy5.5, ICG) and rare-earth or upconversion nanoprobes visualize drainage in real time (Bao et al., 2026; Xiang et al., 2015). DiD-labeled PLO nanovaccines reached inguinal nodes within 2 h and were retained for 48 h, while free dye cleared hepatically (Bao et al., 2026). NIR-II imaging (1000–1700 nm) reduces scattering and autofluorescence, enabling light-driven gold-nanorod/R848 systems to track ablation,

Figure 1. Physicochemical determinants of nanovaccine lymph-node trafficking. (A) Hydrodynamic diameter gates lymphatic entry: particles below ~10 nm partition into blood capillaries and are renally cleared, the 20–50 nm band drains optimally by interstitial convection, 50–100 nm retains good nodal uptake, and constructs above 100–200 nm form an injection-site depot that relies on slow dendritic-cell transport. (B) Surface charge balances interstitial transit against antigen-presenting-cell uptake, with pH-triggered charge-reversal reconciling the two. (C) Geometry, elasticity, and ligand decoration fine-tune the intranodal niche. Synthesized from Farooq et al. (2025), Guo et al. (2024), Huang et al. (2026), and Li et al. (2025).

Figure 2. Antigen–adjuvant co-delivery architecture and innate signaling. Broad antigen sources (whole-tumor-cell lysate or membrane, multi-epitope neoantigens, carrier-free peptide–adjuvant complexes) are paired with synergistic adjuvant combinations (TLR7/8 plus STING, CpG plus Mn2+, MPLA or polysaccharide adjuvants) within polymeric, lipid, biomimetic, or self-assembling vectors. Convergent uptake by node-resident dendritic cells, with endosomal escape to the cytosol, drives NF-κB and IRF3 activation, upregulation of MHC-I/II and costimulatory molecules, type I interferon and IL-12 output, and MHC-I cross-presentation. Synthesized from Huang et al. (2026), Rachamala et al. (2026), Bao et al. (2026), and Zhu et al. (2017).

antigen capture, and nodal migration (Wang et al., 2026) (Table 3).

3.3.2. Nuclear imaging (PET/SPECT) and high-resolution intranodal mapping

PET and SPECT deliver quantitative, whole-body 3D tracking; Copper-64 via NOTA chelation permits %ID/g measurement in sentinel nodes (Zhu et al., 2017). Ex vivo, nodes cleared by passive CLARITY (PACT) and imaged by 3D light-sheet fluorescence microscopy localized albumin-binding complexes (AlbiVax) to subcapsular sinuses and paracortical zones (Zhu et al., 2017) (Table 3; Figure 3).

3.3.3. Magnetic imaging (MRI/MPI) and genetic reporters

Superparamagnetic iron oxide nanoparticles act as T2 MRI and MPI tracers, allowing radiation-free tracking of DC migration over days, and nanoscale coordination-polymer nanovaccines extend the inorganic-core toolkit (Kemp & Kwon, 2021; Yang et al., 2025; Zhao et al., 2019). Firefly luciferase mRNA in LNPs adds a functional genetic readout of in vivo translation (Jin et al., 2024) (Table 3).

3.4. Immunological cascades, TME remodeling, and TLS neogenesis

The ultimate test is whether nodal trafficking becomes systemic, tumor-eradicating immunity; Table 4 and Figure 4 trace that path.

3.4.1. DC maturation, cross-presentation, and memory

On nodal entry, nanovaccines are captured by subcapsular sinus macrophages and CD11c+ DCs (Bao et al., 2026; Farooq et al., 2025). Adjuvant signaling via endosomal TLRs or cytosolic STING drives NF-κB and IRF3 translocation, DC maturation, and IL-12/IFN-β secretion (Jin et al., 2024; Rachamala et al., 2026). Endosomal escape routes antigen into proteasomal processing and MHC-I cross-presentation, expanding tetramer-positive CD8+ CTLs and seeding central and effector memory pools (Bao et al., 2026; Wang et al., 2026) (Figure 4).

3.4.2. TME reprogramming and checkpoint synergy

Activated CTLs and IFN-γ/TNF-α convert “cold” tumors to “hot” (Huang et al., 2026). Neutrophil-targeted biomimetic vaccines (CMNPs) trigger ROS-mediated dsDNA release and tumor-intrinsic cGAS-STING, polarizing N1 neutrophils (Li et al., 2026). Because monotherapy often upregulates PD-L1, pairing with anti-PD-1/PD-L1 blockade overcomes anergy and depletes Tregs and MDSCs (Jin et al., 2024; Rachamala et al., 2026) (Table 4).

3.4.3. Tertiary lymphoid structure neogenesis

Advanced biomimetic systems can nucleate TLS inside tumors. Delivering LIGHT with dual Mn2+/CpG adjuvants induces high endothelial venule neogenesis and CXCL13 release, driving germinal-center maturation and ectopic lymphoid hubs that sustain local immunity (Wang et al., 2026; Wen et al., 2023) (Table 4; Figure 4).

3.5. Translational challenges and future theranostic horizons

Preclinical promise notwithstanding, translation faces familiar hurdles. Fluorophore leaching and tracer dissociation demand covalently bonded radiotracers or stable inorganic cores (Farooq et al., 2025; Uti et al., 2026). Hepatic and splenic RES clearance caps the dose reaching nodes (Rachamala et al., 2026). Multicomponent platforms require GMP compliance, reproducibility, and immunotoxicological profiling (Uti et al., 2026; Zhu et al., 2017). Looking ahead, machine learning for neoantigen prediction and property tuning, coupled with 3D PET/CT and NIR-II readouts, points toward digitally controlled, patient-tailored vaccination (Uti et al., 2026; Ye et al., 2026).

4. Comparative Dynamics of Theranostic Nanovaccine Trafficking, Tracking, and Immunity

4.1. Quantitative dynamics of lymphatic trafficking and interstitial transport

Read across the preclinical record, one pattern keeps reasserting itself: transport into secondary lymphoid organs is set less by chemistry than by a few physical thresholds. Size is the stubborn one. Formulations in the 20–50 nm band move through the porous matrix by convection and show up in draining nodes within about two to four hours, which is fast (Farooq et al., 2025; Guo et al., 2024) (Table 1; Figure 1). The penalty for drifting out of that band is not gentle. PLGA nanovaccines at 83 nm drained well, yet nudging the diameter to 103 and then 122 nm cut nodal uptake by more than 60%, apparently through steric trapping in collagen (Li et al., 2025). At the other extreme, constructs under 10 nm leak into capillaries and are renally cleared before they can do much of anything (Guo et al., 2024; Huang et al., 2026), and once

Table 3. Comparative performance of theranostic imaging modalities for lymph-node tracking. For each modality the table reports the built-in tag or contrast agent, approximate penetration depth and spatial resolution, the primary tracking application, and the quantitative metric or diagnostic advantage. Optical NIR-I/NIR-II, nuclear PET/SPECT, light-sheet microscopy, magnetic MRI/MPI, and genetic bioluminescence reporters are contrasted, underscoring that depth, resolution, and quantitation trade against one another and favor multimodal strategies.

Table 4. Immunotherapeutic efficacy, tumor-microenvironment reprogramming, and tertiary lymphoid structure neogenesis across nanovaccine platforms. The table summarizes, for each system, the tumor model and combination therapy, immune-cell population dynamics (CTL, Treg, M1), tumor-microenvironment and TLS effects, and therapeutic efficacy or survival impact. Platforms combining nanovaccines with immune-checkpoint blockade achieve high regression rates and durable memory, and cascade-engineered biomimetic systems additionally nucleate intratumoral tertiary lymphoid structures.

past roughly 100–200 nm, passive drainage all but stops, leaving slow DC-mediated transport that takes a day or two (Golshan et al., 2017).

Charge matters too, though its effect is more of a tug-of-war than a threshold. Slightly negative to near-neutral surfaces (about −10 to −5 mV) slip past the anionic interstitium and drain quickly, at the cost of weak receptor-independent uptake once they reach the subcapsular sinus (Farooq et al., 2025). Strongly cationic particles (+20 to +35 mV) do the opposite, binding APCs well but snagging in the matrix and the liver (Li et al., 2025). What seems to break the deadlock, at least in the smart formulations, is charge-reversal: hold a mild negative charge in transit, then flip cationic in the acidic sinus or endosome, and DC internalization rises roughly 3.8-fold over non-responsive controls (Li et al., 2025) (Figure 1). Deformability and shape add a final layer. Soft organosilica nanovaccines squeeze through endothelial gaps better than rigid ones, approximately a 10-fold gain in cross-presentation, and nanostars versus nanocages sort themselves into follicular versus paracortical niches (Huang et al., 2026; Li et al., 2025) (Table 1).

4.2. Spatiotemporal resolution and signal kinetics across tracking modalities

No single modality wins outright, which is rather the point of comparing them (Table 3; Figure 3). Nuclear imaging buys depth and numbers. NOTA-decorated 64Cu-AlbiVax, for example, reported 8.5% to 12.3% %ID/g in draining inguinal nodes by 12 h, and when paired with PACT clearing and light-sheet microscopy it placed those complexes in subcapsular macrophages and paracortical DCs rather than in inert stroma (Zhu et al., 2017). Optical methods trade some of that quantitation for speed and radiation-free longitudinal use. DiD-labeled PLO nanovaccines lit up popliteal and inguinal nodes by 2 h and stayed bright for 48 h, while free dye washed out through liver and kidney within about 6 h (Bao et al., 2026); Cy5.5-loaded SPPA cut non-specific hepatic signal by 42% against free dye (Rachamala et al., 2026). NIR-II pushes optical depth past 5 mm (Wang et al., 2026). Magnetic readouts stretch the timescale, SPIO/USPIO give T2 contrast and track DC migration over 7 to 14 days (Kemp & Kwon, 2021; Yang et al., 2025), and Fluc-mRNA adds a functional note, translation beginning by 4 h and peaking near 24 h, tracking CD80/CD86 expression as it goes (Jin et al., 2024).

4.3. APC engagement, cytosolic cross-presentation, and T-cell priming

Once inside the node, the signaling is where the leverage is. Dual-adjuvant formulations, SPPA's 3M-052 plus 2'3'-cGAMP, or CpG paired with Mn2+, engage TLR and STING together and push NF-κB and IRF3 into the nucleus (Huang et al., 2026; Rachamala et al., 2026). The readouts are consistent: a 4- to 6-fold rise in surface MHC-I, MHC-II, CD80, CD86, and CD40 on CD11c+ DCs, with IL-12p70, TNF-α, and type I interferons to match (Bao et al., 2026; Jin et al., 2024) (Figure 2). The harder step, and the one that separates a good vaccine from a mediocre one, is endosomal escape. Proton-sponge polymers, fusogenic lipids, or photothermal cores destabilize the endosome, letting antigen reach the cytosol for proteasomal processing and MHC-I loading (Bao et al., 2026; Li et al., 2025). Where that works, cross-presenting CD8α+ and CD103+ DCs expand tetramer-positive CTLs roughly 5- to 8-fold over soluble controls (Rachamala et al., 2026), and the memory compartment, central and effector, holds up past 120 days against rechallenge (Bao et al., 2026; Wang et al., 2026) (Figure 4).

4.4. TME remodeling, checkpoint synergy, and TLS neogenesis

The systemic payoff is TME remodeling. CXCL9/CXCL10-guided CD8+ CTLs infiltrate primary and metastatic sites and flip the microenvironment from cold to hot (Huang et al., 2026; Wang et al., 2026) (Table 4). Across hepatocellular and melanoma models, intratumoral CD8+/Treg ratios climbed 8- to 12-fold with M2-to-M1 repolarization (Jin et al., 2024; Rachamala et al., 2026), and neutrophil-targeted CMNPs, by releasing dsDNA and firing cGAS-STING, suppressed primary liver tumor growth by over 85% (Li et al., 2026). Monotherapy, though, tends to trip its own brake: IFN-γ-driven PD-L1 upregulation (Jin et al., 2024). Adding anti-PD-1/PD-L1 blockade restored function and produced complete eradication in 60% to 90% of animals across B16F10, 4T1, and MC38 models (Rachamala et al., 2026) (Table 4; Figure 4). Beyond the node itself, cascade-engineered biomimetic systems delivering LIGHT with Mn2+/CpG nucleated ectopic TLS, high endothelial venules, CXCL13, and functional germinal centers, inside the tumor stroma, blunting metastatic seeding (Wang et al., 2026; Wen et al., 2023).

Figure 3. Comparative landscape of theranostic imaging modalities for in vivo lymph-node tracking. Each modality is positioned by approximate tissue penetration depth (x-axis, log scale) and spatial resolution (y-axis, log scale; finer resolution upward), with bubble size indicating relative throughput. Optical NIR-I/NIR-II fluorescence offers rapid, radiation-free monitoring at shallow to intermediate depth; PET and SPECT provide quantitative whole-body depth; light-sheet microscopy gives sub-cellular ex vivo mapping; MRI/MPI and bioluminescence reporters occupy complementary niches. Synthesized from Kemp & Kwon (2021), Wang et al. (2026), Yang et al. (2025), and Zhu et al. (2017).

Figure 4. From nodal priming to tumor remodeling and tertiary lymphoid structure neogenesis. Lymph-node priming (dendritic-cell maturation and MHC-I cross-presentation) expands antigen-specific CD8+ cytotoxic T lymphocytes and durable memory, which reprogram the tumor microenvironment (CXCL9/10 influx, M1 repolarization, reduced Tregs and MDSCs). Adaptive PD-L1 upregulation is overcome by anti-PD-1/PD-L1 checkpoint blockade, yielding 60–90% regression, while LIGHT plus Mn2+/CpG cascades nucleate intratumoral tertiary lymphoid structures. Synthesized from Wang et al. (2026), Wen et al. (2023), Rachamala et al. (2026), and Jin et al. (2024).

5. Reconciling Delivery Physics, Imaging Fidelity, and Immunological Payoff

5.1. A unifying design logic, and its tensions

If there is a single lesson in this body of work, it is that the parameters we like to optimize separately are not actually independent. Size, charge, shape, and ligand chemistry each pull on drainage and on uptake at once, and often in opposite directions (Farooq et al., 2025; Li et al., 2025) (Figure 1). The clearest example is the charge problem: what helps a particle drain is almost exactly what keeps an APC from taking it up. Charge-reversal designs are elegant precisely because they refuse to choose, staying anionic in transit and turning cationic on arrival (Li et al., 2025). Whether that elegance survives GMP scale-up is a separate question, and not a trivial one (Table 1).

5.2. What imaging can, and cannot, tell us

The imaging story is genuinely enabling, but it deserves a little skepticism. A bright node is reassuring; it is not proof that intact nanoparticles are there. Fluorophore leaching can report a signal that has already dissociated from its carrier, which is why covalently bonded radiolabels or stable inorganic cores matter more than they might first appear (Farooq et al., 2025; Uti et al., 2026) (Table 3). No modality escapes trade-offs. PET and SPECT give the numbers and the depth but not the cellular detail; light-sheet microscopy gives exquisite sub-organ maps but only ex vivo; NIR-II reaches deeper than NIR-I yet still contends with tissue (Wang et al., 2026; Zhu et al., 2017) (Figure 3). The sensible path, and the one the better studies already take, is multimodal, pairing a quantitative tracer with a high-resolution or functional readout rather than trusting any one channel (Jin et al., 2024; Kemp & Kwon, 2021).

5.3. From nodal metrics to immunological outcome

The correlation that the field most wants, early imaging biomarker predicting late clinical benefit, is still more aspiration than established fact. We can measure %ID/g, transit time, and subcapsular versus paracortical localization; we can measure CTL expansion, memory frequency, and survival (Bao et al., 2026; Rachamala et al., 2026; Zhu et al., 2017). Linking the two with rigor, across platforms and models, is the work that has not really been done at scale (Figure 4). The mechanistic chain is plausible and increasingly well supported, nodal delivery to DC maturation to cross-presentation to memory and TME remodeling (Table 2; Table 4), but plausibility is not the same as a validated surrogate endpoint, and it would be a mistake to treat it as one (Uti et al., 2026; Ye et al., 2026).

5.4. Translational bottlenecks and a realistic outlook

The barriers that remain are, frankly, the unglamorous ones. RES sequestration still siphons dose to liver and spleen (Rachamala et al., 2026). Multicomponent theranostic particles are hard to make reproducibly, and harder to make under GMP, and their immunotoxicology is not fully charted (Uti et al., 2026; Zhu et al., 2017). None of this argues against the approach; it argues for patience and for standardization. The near-term promise, coupling 3D PET/CT or NIR-II tracking with dynamic immunomonitoring, and using machine learning to tune both antigen and carrier, is real, but it will be realized formulation by formulation rather than in one leap (Uti et al., 2026; Wang et al., 2026; Ye et al., 2026).

6. Conclusion

Immunomodulatory nanovaccines carrying built-in imaging tags reframe lymph-node delivery as something that can be watched, measured, and corrected rather than merely assumed. The evidence converges on a coherent design logic: particle size in the 20–50 nm window, tuned surface charge with stimuli-responsive reversal, deliberate geometry and elasticity, and ligand targeting together govern nodal drainage and APC engagement. Co-delivered antigen–adjuvant payloads then drive DC maturation, MHC-I cross-presentation, durable memory, and checkpoint-synergistic tumor control, in advanced systems extending to intratumoral TLS neogenesis. Optical, nuclear, magnetic, and genetic readouts make these steps quantifiable in vivo. Realizing the clinical promise now depends less on new chemistry than on probe stability, controlled RES clearance, and reproducible GMP manufacturing.

References